Research Article:
Menstrual Disorder in Morbid Obese Patients, Compared to Normal-weighted Controls

Zeinab Tamannaie1, Fatemeh Jesmi2, Meisam Akhlaghdoust2, Shahla Chaichian3, Abdolreza Pazouki1, Somayeh Mokhber1, Mahdesht Pishghahroudsari1

1. Minimally Invasive Surgery Research Center, Iran University of Medical Sciences, Tehran, Iran.
2. Pars Advanced and Minimally Invasive Medical Manners Research Center, Pars Hospital, Iran University of Medical Sciences, Tehran, Iran.

* Corresponding Author:
Shahla Chaichian, MD.
Address: Pars Advanced and Minimally Invasive Medical Manners Research Center, Pars Hospital, Iran University of Medical Sciences, Tehran, Iran.
E-mail: shchaichian@gmail.com

ABSTRACT

Background: The present study aimed to evaluate the association between menstrual cycle disorders and obesity in Iranian women.

Methods and Materials: In the present case-control study, 405 obese women of reproductive age who were referred to the Obesity Clinic of Minimally Invasive Surgery Research Center, Rasoul-e-Akram Hospital, in Tehran City, Iran between Jan 2013 and Oct 2015 were included as the case group. Moreover, they were compared with a control healthy-weight group, selected from their family members (n=293). Menstrual cycle characteristics were documented in a researcher-designed checklist. All statistical analyses were performed in SPSS and STATA.

Results: In the case group, 47(11.6%) women had irregular menstrual cycles, while it existed in 22(7.5%) members of the control group (P<0.001). The prevalence of different menstrual disorders was as follows: polymenorrhea 107(26.4%) in the cases and 51(17.4%) in the controls (P<0.001); oligomenorrhea 22(5.4%) in the cases and 16(5.5%) in the controls (P<0.001).

Conclusion: The present study results indicated that morbid obesity increases the risk of menstrual irregularities and dysmenorrhea; therefore, it is essential to pay greater attention to this issue in morbidly obese patients for the proper management of this disturbing comorbidity.

1. Introduction

Obesity and overweight are growing public health problems in numerous countries, as they elevate the global risk of severe morbidity and mortality [1]. The prevalence of obesity is estimated to be approximately 22% in Iranian adults [2]. Morbid obesity increases the risk of cardiovascular diseases, diabetes mellitus, as well as gynecological problems, including infertility, Polycystic Ovarian Syndrome (PCOS), and menstruation disturbances [3]. PCOS, a common endocrine disorder, characterized by clinical and biochemical hyperandrogenism and chronic anovulation, polycystic ovaries in ultrasonography findings, is frequently associated with morbid obesity [4]. The prevalence of...
Menstrual disorders differ among various countries; it is reported as high as 30.1% in some Iranian studies [5]. Several studies identified a two-fold increase in the prevalence of menstrual cycle irregularities in obese women of reproductive age; that rate is hypothesized to be due to the increased secretion of testosterone from and peripheral adipose tissue [6, 7]. Additionally, most cases of menstruation irregularities resolve after obesity surgery [8].

However, cultural and geographical issues, such as light exposure, work-shifts, diet, and sleep pattern affect menstrual cycles, as well as obesity status [9-11]; thus, it is essential to separately study the prevalence of menstruation disturbances and their association with obesity in different nations. Iranian studies addressing the prevalence and the factors associated with menstrual disorders in Iranian women are scarce. The available studies have focused on adolescents or included insufficient sample sizes [12-14]. Therefore, the present study aimed to examine the association between menstrual cycle disorders and obesity in Iranian obese females, compared to their healthy-weighted counterparts, to understand the impact of obesity on menstrual irregularity.

2. Materials and Methods

The present case-control study enrolled 405 consecutively obese women of reproductive age (aged 15-50 years) who were referred to the Obesity Clinic of Minimally Invasive Surgery Research Center, a referral outpatient center at Rasoul-e-Akram Hospital, in Tehran City, Iran between Jan 2013 and Oct 2015. This study was approved by the Research Ethics Committee of Iran University of Medical Sciences and the study participants provided a signed written informed consent form.

After the inclusion of patients as the case group, by convenience sampling method, eligible control subjects consisted of healthy-weight family members of the cases (n=293), obtained through frequency matching. The exclusion criteria of the case group consisted of current breastfeeding, pregnancy, menopause, documented PCOS (according to Rotterdam criteria), a history of ovulation disorders, uterine/genitalia abnormalities, uterine fibroids, and using contraceptives in the past 6 months. After consultation, the research participants were visited and interviewed by a gynecologist, who recorded the patient’s age and menstrual cycle characteristics, documented in a written questionnaire.

In the checklist, menstrual cycle characteristics, including the intervals between the menstrual cycles, the duration of the menstrual cycles, the extent of menstrual bleeding, and menstrual cycle changes during the past 12 months were probed.

Menstrual cycles were defined as a short cycle or polymenorrhea (≤25 days), normal cycle (26–34 days), and long cycle or oligomenorrhea (≥35 days). If it followed no similar pattern, it was considered irregular. Dysmenorrhea was considered positive menstrual pain.

Furthermore, a research team member documented the study participant’s weight and height for calculating Body Mass Index (BMI) as weight in kilograms divided by squared height in meters (kg/m²). The study participants’ height was measured by a wall measuring tape using a digital stadiometer (Seca Inc, USA) with an accuracy of 0.1 cm in a barefoot standing position. The research participants’ weight was measured by a calibrated digital weight scale with a measurement accuracy of 0.1 kg with light clothing. The international classification of adult underweight, overweight, and obesity according to BMI (World Health Organization classification) was considered in the present study; it classifies BMI 18-24.99 kg/m² as normal and ≥40 kg/m² as class III (morbid) obesity.

We used SPSS and STATA for statistical analysis. The quantitative data were expressed as Mean±Standard Deviation (SD) with 95% Confidence Intervals (95%CI); for the qualitative data, the frequency was used. The Chi-squared test and Independent Samples t-test was used to compare the collected qualitative and quantities data, respectively. To evaluate the association between regular/irregular menstruation, dysmenorrhea, polymenorrhea, and oligomenorrhea between non-obese and obese participants, we used logistic regression analysis; we calculated Odds Ratio (OR) and 95% CIs for this purpose.

3. Results

We included 405 morbidly obese women (case group) with the Mean±SD age of 33.72±7.77 years and the mean±SD BMI of 37.55±8.64 kg/m² as well as 293 normal-weight women (control group) with the Mean±SD age of 27.42±7.24 years and the Mean±SD BMI of 21.82±1.70 kg/m²; the research groups were comparable regarding mean age (P>0.05) (Table 1).

In the case group, there were 125 women with irregular menstrual cycles, representing a prevalence of irregular menstrual cycles of 30.9%. Moreover, in the control group, the prevalence was calculated as 17.1% (n=50) (OR=1.99, 95%CI=1.00-3.01) (Tables 2 & 3). The prevalence of polymenorrhea was equal to 64% (n=80) in the case group, i.e., significantly lower in the control
group (48%, n=24) (OR=1.66, 95%CI=1.18-2.34). The prevalence of oligomenorrhea was measured to be 36% (n=45) in the case group, i.e., significantly lower in the control group (52%, n=26) (OR=1.90, 95%CI=1.23-2.18) (Tables 2 & 3). The prevalence of dysmenorrhea was significantly higher in the case group (64.2%, n=260), compared to the control group (41.9%, n=123) (P<0.001, OR=2.55, 95%CI=1.20-3.82).

4. Discussion

In the present study, the prevalence of menstruation disturbances morbidly was compared between the obese women of reproductive age with matched-for-age normal-weighted controls. As per the collected results, there was a nearly two-fold (OR=1.99) increase in the prevalence of irregular menstrual cycles in the obese group (30.9%), compared to the controls (17.1%), as well as polymenorrhea (64% vs. 48%, respectively), and dysmenorrhea (64.2% vs. 41.9%, respectively); however, the prevalence of oligomenorrhea was approximately two-fold higher (OR=1.90) in the control group (52%), compared to the case group (36%).

Menstrual cycle disturbances and obesity are of great importance, as they can impair the quality of life and

Table 1. Comparing the baseline characteristics of the study groups

<table>
<thead>
<tr>
<th>Variable</th>
<th>Non-obese Group (n=293)</th>
<th>Obese Group (n=405)</th>
<th>P</th>
<th>95%CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y</td>
<td>27.42±7.24</td>
<td>33.72±7.77</td>
<td>0.0001</td>
<td>-30.09-28.63</td>
</tr>
<tr>
<td>Height, m</td>
<td>164.15±6.50</td>
<td>162.41±5.93</td>
<td>0.0001</td>
<td>-162.03-161.09</td>
</tr>
<tr>
<td>Weight, kg</td>
<td>58.88±6.51</td>
<td>99.03±23.06</td>
<td>0.0001</td>
<td>-82.56-78.63</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>21.82±1.70</td>
<td>37.55±8.64</td>
<td>0.0001</td>
<td>-30.10-28.63</td>
</tr>
</tbody>
</table>

Table 2. The menstrual characteristics of the study groups

<table>
<thead>
<tr>
<th>Variable</th>
<th>Non-obese Group (n=293)</th>
<th>Obese Group (n=405)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Regular menstruation</td>
<td>Yes</td>
<td>243(82.9)</td>
<td>280(69.1)</td>
</tr>
<tr>
<td></td>
<td>No</td>
<td>50(17.1)</td>
<td>125(30.9)</td>
</tr>
<tr>
<td>Intermenstrual bleeding (Spotting)</td>
<td>Yes</td>
<td>79(26.9)</td>
<td>78(19.3)</td>
</tr>
<tr>
<td></td>
<td>No</td>
<td>214(73.1)</td>
<td>327(80.7)</td>
</tr>
<tr>
<td>Menorrhagia</td>
<td>Yes</td>
<td>22(7.5)</td>
<td>52(12.8)</td>
</tr>
<tr>
<td></td>
<td>No</td>
<td>271(92.5)</td>
<td>353(87.2)</td>
</tr>
<tr>
<td>Premenstrual bleeding (Spotting)</td>
<td>Yes</td>
<td>84(28.6)</td>
<td>128(31.6)</td>
</tr>
<tr>
<td></td>
<td>No</td>
<td>209(71.4)</td>
<td>277(68.4)</td>
</tr>
<tr>
<td>Premenstrual syndrome (PMS)</td>
<td>Yes</td>
<td>190(64.8)</td>
<td>304(75.1)</td>
</tr>
<tr>
<td></td>
<td>No</td>
<td>103(35.2)</td>
<td>101(24.9)</td>
</tr>
<tr>
<td>Dysmenorrhea</td>
<td>Yes</td>
<td>123(41.9)</td>
<td>260(64.2)</td>
</tr>
<tr>
<td></td>
<td>No</td>
<td>170(58.1)</td>
<td>145(35.8)</td>
</tr>
</tbody>
</table>
fertility of the woman [15]; therefore, studying the association of obesity and menstruation disturbances is of high significance. Several studies have addressed this issue worldwide. Nevertheless, studies on Iranian women are scarce. In the study by Castillo-Martínez et al., the prevalence of irregular menstruation was measured to be 34.4% in obese women [6], i.e., close to the percentage in the present study (30.9%). Similarly, they reported a significant association between menstrual cycle irregularities and the grade of obesity, independent of PCOS or diabetes mellitus [6], i.e., in line with the present study data. Other studies have also documented a higher frequency of menstrual irregularities in obese and morbidly obese women, including irregular cycles, polymenorrhea, and oligomenorrhea, and oligomenorrhea [16, 17], which support the present study findings. Wei et al. also reported a two-fold increase in the prevalence of irregular cycles in obese patients (26% in patients with a BMI ≥30 kg/m² vs. 14% in patients with a BMI <30 kg/m²) [7], i.e., consistent with the current research results. However, in their study, obese patients provided a higher frequency of long cycles (clinically parallel to oligomenorrhea) and lower frequency of short cycles (clinically parallel to polymenorrhea), which oppose the results of the current study; in the present study, polymenorrhea was more frequent in morbidly obese patients and oligomenorrhea was more prevalent in normal-weighted than morbidly obese patients. These data discrepancies can be attributed to multiple issues. First, the measurement of BMI (self-report vs. measurement) and the method of recording the data of the participants’ menstruation are different among studies that can affect the results. Second, the patients of the case group in the present study were morbid obese patients (BMI ≥40 kg/m²), while the results of previous studies reported the results for obese patients without classification of obesity grade [7]. All the above-mentioned studies confirmed higher menstrual irregularities in obese patients, compared to the normal-weighted population, i.e., in line with the present study, despite some minor discrepancies in details. Considering multiple factors that affect menstrual cycles, these differences are justifiable. Due to the significance of menstrual disorders in women’s life, it is essential to pay further attention to this issue in morbidly obese patients.

Another critical finding of the present study was the higher prevalence of dysmenorrhea in the case group (64.2%), compared to the controls (41.9%). Previous international and domestic studies have also investigated obesity as a risk factor for dysmenorrhea. Ju et al. reported a 1.22-fold increased risk of dysmenorrhea in obese patients in a U-shaped association [18], i.e., consistent with the results of the present study. However, in the present study, the OR of dysmenorrhea was higher than their study; it can be justified to be due to the selection of morbidly obese patients in the current study. In a review study, various factors have been associated with dysmenorrhea, including age, parity, oral contraceptives use, stress, and positive family history, although obesity failed to demonstrate a significant association in this respect [19]. Another study (on the Iranian population) considered obesity not associated with dysmenorrhea [20]; however, in the present study, morbidly obese patients provided a 2.5-fold higher risk of dysmenorrhea. This discrepancy can be since we have only considered morbid obese patients that can have different health statuses than other obesity categories.

The main strength of the present study included studying the association between morbid obesity and menstrual disorders, compared to a matched control group, in the Iranian population, i.e., disregarded before. Furthermore, the study results might have been affected by some limitations, like selecting participants from one center and one city.
of Iran, which limits the generalizability of the results to the whole Iranian population. Moreover, the data on the menstrual cycles of patients was collected by self-report, which can be affected by recall bias, i.e., due to the nature of the data. Additionally, we only measured BMI, while other parameters, like upper-body fat and waist circumference, could also affect the collected results.

5. Conclusion

The present study data indicated that morbid obesity increases the risk of menstrual irregularities and dysmenorrhea; therefore, it is essential to pay greater attention to this issue in morbidly obese patients for the proper management of this disturbing comorbidity.

Ethical Considerations

Compliance with ethical guidelines

This study was approved by the Research Ethics Committee of Iran University of Medical Sciences. All ethical principles are considered in this article. The participants were informed about the purpose of the research and its implementation stages. They were also assured about the confidentiality of their information. They were free to leave the study whenever they wished, and if desired, the research results would be available to them.

Funding

This research did not receive any grant from funding agencies in the public, commercial, or non-profit sectors.

Authors’ contributions

All authors equally contributed to preparing this article.

Conflict of interest

The authors declared no conflict of interest.

References


